Abstracts tagged "SLE"

Abstract Number: 736 • 2015 ACR/ARHP Annual Meeting
Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies
H. Michael Belmont¹, Janet Nwaukoni² and Jill P. Buyon², ¹Hosp for Joint Disease, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: We and others have suggested that complement activation can serve as an initiating signal that increases the thrombosis risk in SLE patients with antiphospholipid antibodies.…
Abstract Number: 820 • 2015 ACR/ARHP Annual Meeting
Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Mikhail Olferiev, David Fernandez, Leila Khalili, Dina Greenman, Mary K. Crow and Kyriakos A. Kirou, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Decreases in peripheral blood levels of complement components of C3 and C4 are associated with SLE and often indicate a lupus flare. The aim…
Abstract Number: 1777 • 2015 ACR/ARHP Annual Meeting
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Li Chun Wang¹, Stuart Perper¹, Kimberly Black¹, Regina Mario¹, Candace Graff^2,3, Dawna Hartman³, Andrew Souers⁴, Steven Elmore⁴ and Lisa Olson^1,3, ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. We report here that continuous daily treatment with 30mpk venetoclax…
Abstract Number: 1870 • 2015 ACR/ARHP Annual Meeting
A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities
Yogita Ghodke-Puranik¹, Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin², Ashima Makol³, Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi Chowdhary⁴, Mark A. Jensen⁵ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, autoimmune disease characterized by autoantibodies to nucleic acids and nucleosomal proteins. The type I interferon pathway is…
Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Maria Boge Lauvsnes¹, Anne Bolette Tjensvoll², Ingeborg Kvivik³, Roald Omdal⁴ and Chaim Putterman⁵, ¹Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ³Reasearch Department, Stavanger University Hospital, Stavanger, Norway, ⁴Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…
Abstract Number: 739 • 2015 ACR/ARHP Annual Meeting
Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Katharine Hickman¹, Laurence S Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: An increasing number of studies have investigated factors that are associated with thrombosis in SLE. However, few have examined risk factors specific for venous…
Abstract Number: 1066 • 2015 ACR/ARHP Annual Meeting
Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations
Narender Annapureddy¹, Achint Patel², Rabi Yacoub³, Krishna Pakanati⁴, Shiv Agarwal⁵, Priya Simoes⁶, Sunil Kamat⁷, Alexandre Benjo⁸ and Girish Nadkarni⁹, ¹Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ²Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Gateway Medical Center, Clarksville, TN, ⁵Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, ⁶Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, ⁷Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, ⁸Ochsner Clinic Foundation, New Orleans, NY, ⁹Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Cardiovascular disease remains the most common cause of mortality in Systemic lupus erythematosus (SLE). Some studies suggest that mortality due to acute myocardial infarction…
Abstract Number: 1780 • 2015 ACR/ARHP Annual Meeting
Oxidative Stress Protects Against Nephritis Induced By Chronic Graft Versus Host Disease
Zachary Oaks¹, Adam Bartos², Miguel Beckford³, Mark Haas⁴ and Andras Perl⁵, ¹Medicine, SUNY Upstate, Syracuse, NY, ²Medicine, SUNY, Syracuse, NY, ³SUNY Upstate, Syracuse, NY, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Department of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by glutathione depletion and oxidative stress in T cells which lead to abnormal lineage development and dysfunction. In…
Abstract Number: 1871 • 2015 ACR/ARHP Annual Meeting
Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families
Rufei Lu¹, Hua Chen¹, Krista Bean¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James^1,2, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine & Pathology, Univ. of Oklahoma, Okla, OK
Background/Purpose: Many systemic autoimmune diseases share heritable and non-heritable risks, as well as some clinical manifestations. A recent meta-analysis based upon genome-wide genetic studies contrasting…
Abstract Number: 3025 • 2015 ACR/ARHP Annual Meeting
FcγRIIIa-Psyk Signaling up-Regulates TLR3 and TLR5 in Human Naïve CD4+ T-Cells
Chen Chen¹, Ye Bi², Terry Moore³ and Anil K. Chauhan⁴, ¹Rheumatology/Internal Medicine, Saint Louis University, St. Louis, MO, ²Internal Medicine, Saint Louis University, St. Louis, MO, ³Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO, ⁴Internal Medicine-Rheumatology, Saint Louis University, St Louis, MO
Background/Purpose: To delineate mechanism of FcγRIIIa-pSyk signal in TH17 and IFN-γhigh subset development. To examine whether Toll-like receptor signaling play a role in CD4+ T-cell…
Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
May Choi¹, John G. Hanly², Murray Urowitz^3,4, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Daniel J Wallace⁹, Joan T. Merrill¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Ellen M. Ginzler¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian N. Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Kristján Steinsson²³, Ola Nived²⁴, Gunnar K. Sturfelt²⁵, Susan Manzi²⁶, Munther Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Guillermo Ruiz-Irastorza³⁰, S. Sam Lim³¹, Thomas Stoll³², Murat Inanc³³, Kenneth C. Kalunian³⁴, Diane L. Kamen³⁵, Peter Maddison³⁶, Christine A. Peschken³⁷, Søren Jacobsen³⁸, Anca Askanase³⁹, Jill P. Buyon⁴⁰, W. Winn Chatham⁴¹, Manuel Ramos-Casals⁴², Yvan St. Pierre⁴³, Ann E. Clarke⁴⁴ and Marvin J. Fritzler¹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Rheumatology, TWH, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁷Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁹Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹²Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹³Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁴Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ¹⁹UNC Kidney Centre, Chapel Hill, NC, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁵Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁶Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁷Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²⁹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁵Medicine, Medical University of South Carolina, Charleston, SC, ³⁶School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³⁷Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ³⁸Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁹Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁰Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴¹Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴²Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴⁴Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…
Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Anna R. Broder¹, Candace H. Feldman², Anand Kumthekar³, Michail Alevizos⁴, Hongshu Guan⁵, Medha Barbhaiya⁶ and Karen H. Costenbader⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Internal Medicine, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…
Abstract Number: 1784 • 2015 ACR/ARHP Annual Meeting
Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Johanna Nagel¹, Tore Saxne², Pierre Geborek³, Anders A. Bengtsson⁴, Søren Jacobsen⁵, Charlotte Sværke Jørgensen⁶, Andreas Jönsen⁷ and Meliha C. Kapetanovic³, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ⁵Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁶Department of Microbiological Diagnostics & Virology, Statens Serum Institut, Copenhagen, Denmark, ⁷Department of Rheumatology, Lund University Hospital, Lund, Sweden
Background/Purpose: To explore the impact of SLE disease and belimumab given in addition to standard of care therapy on antibody response after vaccination with PCV13…
Abstract Number: 2045 • 2015 ACR/ARHP Annual Meeting
Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus
Jasmine Nguyen¹, Tricia Williams², Earl Silverman³ and Deborah M. Levy⁴, ¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²Psychology, Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neurocognitive impairment (NCI) is an important morbidity in childhood-onset systemic lupus erythematosus (cSLE); however, the gold standard formal neuropsychological assessment is difficult to access. Screening for…
Abstract Number: 3030 • 2015 ACR/ARHP Annual Meeting
Increased Localization of Spleen Tyrosine Kinase (Syk) in Lipid Rafts of in Vitro TCR/CD3-CD28 Activated Lupus T Cells
Noymar Luque¹, Nursamaa Abdoel¹, Héctor Rojas², Martín Rodríguez¹, Gloria Vásquez³ and Ana Blasini¹, ¹Centro Nacional de Enfermedades Reumáticas. Hospital Universitario de Caracas, Caracas, Venezuela, ²Instituto de Inmunología, Escuela de Medicina, Universidad Central de Venezuela, Caracas, Venezuela, ³Grupo de Inmunología Celular e Inmunogenética. Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Numerous alterations in signal transduction in SLE T cells have been previously reported. Diminished expression of the ζ chain of the TCR/CD3 complex has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].